{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:53:21Z","timestamp":1792162401280,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.encep.2018.11.003","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T09:21:21Z","timestamp":1545211281000},"page":"232-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["\u00c9tude co\u00fbt-efficacit\u00e9 du pamoate d\u2019olanzapine\u00a0: analyse en miroir sur un an"],"prefix":"10.1016","volume":"45","author":[{"given":"J.","family":"Potaufeu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Langr\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Drapier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Burgot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Marie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.encep.2018.11.003_bib0155","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1023\/A:1025499131905","article-title":"Assessment and treatment selection for \u201crevolving door\u201d in patients with schizophrenia","volume":"68","author":"Weiden","year":"1997","journal-title":"Psychiatr Q"},{"key":"10.1016\/j.encep.2018.11.003_bib0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00019053-200018020-00002","article-title":"Patient compliance with drug therapy in schizophrenia: economic and clinical issues","volume":"18","author":"Lindstrom","year":"2000","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.encep.2018.11.003_bib0165","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.encep.2018.11.003_bib0170","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/schbul\/21.3.419","article-title":"Cost of relapse in schizophrenia","volume":"21","author":"Weiden","year":"1995","journal-title":"Schizophr Bull"},{"issue":"3","key":"10.1016\/j.encep.2018.11.003_bib0175","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.encep.2018.11.003_bib0180","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0013-7006(06)72689-6","article-title":"L\u2019observance th\u00e9rapeutique\u00a0: un objectif essentiel","volume":"32","author":"Misdrahi","year":"2006","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2018.11.003_bib0185","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0013-7006(13)70121-0","article-title":"Recommandations formalis\u00e9es d\u2019experts de l\u2019AFPBN\u00a0: prescription des neuroleptiques et antipsychotiques d\u2019action prolong\u00e9e","volume":"39","author":"Samalin","year":"2013","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2018.11.003_bib0190","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0924-9338(14)70001-X","article-title":"Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics","volume":"29","author":"Heres","year":"2014","journal-title":"Eur Psychiatry"},{"issue":"1","key":"10.1016\/j.encep.2018.11.003_bib0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S1092852913001016","article-title":"Long-acting injectable antipsychotics: shall the last be first?","volume":"19","author":"Stahl","year":"2014","journal-title":"CNS Spectr"},{"issue":"5","key":"10.1016\/j.encep.2018.11.003_bib0200","doi-asserted-by":"crossref","first-page":"790","DOI":"10.4088\/JCP.v69n0512","article-title":"An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia","volume":"69","author":"Lauriello","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.encep.2018.11.003_bib0205","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1176\/appi.ajp.2009.07081221","article-title":"Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia","volume":"167","author":"Kane","year":"2010","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.encep.2018.11.003_bib0210","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/YIC.0000000000000038","article-title":"Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study","volume":"29","author":"McDonnell","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2018.11.003_bib0215","series-title":"D\u00e9cret no\u00a02012-1116\u00a0du 2\u00a0octobre 2012\u00a0relatif aux missions m\u00e9dico\u00e9conomiques de la Haute Autorit\u00e9 de sant\u00e9","year":"2012"},{"issue":"8\u00a0Suppl","key":"10.1016\/j.encep.2018.11.003_bib0220","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jclinepi.2013.01.012","article-title":"Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry","volume":"66","author":"Kane","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.encep.2018.11.003_bib0225","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4088\/JCP.13r08440","article-title":"Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies","volume":"74","author":"Kishimoto","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2018.11.003_bib0230","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00019053-200523001-00004","article-title":"Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis","volume":"23","author":"De Graeve","year":"2005","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.encep.2018.11.003_bib0235","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0013-7006(05)82390-5","article-title":"Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation","volume":"31","author":"Llorca","year":"2005","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2018.11.003_bib0240","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00019053-200523001-00005","article-title":"Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany","volume":"23","author":"Laux","year":"2005","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.encep.2018.11.003_bib0245","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00148365-200806010-00004","article-title":"E-STAR Study Group. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain","volume":"6","author":"Olivares","year":"2008","journal-title":"Appl Health Econ Health Policy"},{"issue":"3","key":"10.1016\/j.encep.2018.11.003_bib0250","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.psychres.2013.07.012","article-title":"Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations","volume":"210","author":"Wu","year":"2013","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.encep.2018.11.003_bib0255","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1600-0447.2009.01352.x","article-title":"Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use","volume":"120","author":"Taylor","year":"2009","journal-title":"Acta Psychiatr Scand"},{"issue":"11","key":"10.1016\/j.encep.2018.11.003_bib0260","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2165\/11537680-000000000-00000","article-title":"Comparative effectiveness of long-acting risperidone in New Zealand","volume":"30","author":"Carswell","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.encep.2018.11.003_bib0265","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/NDT.S77778","article-title":"Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia","volume":"11","author":"Zhang","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.encep.2018.11.003_bib0270","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3111\/13696998.2014.979936","article-title":"Hospitalization rates in patients switched from oral antipsychotics to aripiprazole once-monthly: final efficacy analysis","volume":"18","author":"Kane","year":"2015","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.encep.2018.11.003_bib0275","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200303000-00003","article-title":"High-dose olanzapine for treatment-refractory schizophrenia","volume":"26","author":"Lerner","year":"2003","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"10.1016\/j.encep.2018.11.003_bib0280","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4088\/PCC.v08n0410a","article-title":"High-Dose Olanzapine Orally Disintegrating Tablets for Treatment-Resistant Psychosis","volume":"8","author":"Qadri","year":"2006","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.encep.2018.11.003_bib0285","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4236\/ojpsych.2012.24037","article-title":"Very-high-dose olanzapine for treatment-resistant schizophrenia","volume":"2","author":"Batail","year":"2012","journal-title":"Open J Psychiatry"},{"issue":"7-8","key":"10.1016\/j.encep.2018.11.003_bib0290","first-page":"421","article-title":"Schizophr\u00e9nie\u00a0: \u00e9valuation du co\u00fbt de la prise en charge","volume":"27","author":"Raymond","year":"2009","journal-title":"J Econ Med"},{"key":"10.1016\/j.encep.2018.11.003_bib0295","series-title":"Approche pharmaco\u00e9conomique\u00a0: \u00e9valuation pharmao-m\u00e9dico\u00e9conomique de strat\u00e9gies th\u00e9rapeutiques\u00a0: \u00e9l\u00e9ments de m\u00e9thodologie","first-page":"40","author":"Woronoff-Lemsi","year":"2000"},{"key":"10.1016\/j.encep.2018.11.003_bib0150","doi-asserted-by":"crossref","first-page":"212","DOI":"10.7573\/dic.212267","article-title":"Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients","volume":"4","author":"Kamat","year":"2015","journal-title":"Drugs Context"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700618302355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700618302355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T10:54:14Z","timestamp":1562151254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700618302355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0013700618302355"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2018.11.003","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9tude co\u00fbt-efficacit\u00e9 du pamoate d\u2019olanzapine\u00a0: analyse en miroir sur un an","name":"articletitle","label":"Article Title"},{"value":"L'Enc\u00e9phale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.encep.2018.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 L'Enc\u00e9phale, Paris.","name":"copyright","label":"Copyright"}]}}